Information required for submission of resistant strain to Medicines for Malaria Venture’s 13th Call for Proposals

Deadline for receipt in MMV office: 12 noon (CET) March 31st, 2015

Please read the instructions carefully. Submissions should be completed on 1-2 pages of A4 using the template given. MMV will only receive submissions electronically; please see the accompanying templates and contact details at the end of this document.

Antimalarial drug resistance is a constant and ever present risk and MMV is committed to delivering the next generation of anti-malarials that demonstrate activity against all known resistant parasites. To help with this, MMV is keen to source stable parasite cultures that show significant resistance to any of the drugs listed below:

Piperaquine, Pyronaridine, Mefloquine, Amodiaquine, Lumefantrine

The aim would be to:
1. Confirm the resistance phenotype via blinded compound testing
2. If resistance confirmed then, once any necessary agreements are in place, for the parasites to be shipped to Swiss Tropical and Public Health Institute at MMV’s expense where it would be cultured and added to MMV’s existing panel of strains for testing against new clinical candidates.

To complete the submission form for resistant strains it is critical to state which compounds the strain(s) are resistant too and on what basis (e.g. comparative data between a fully sensitive and resistant strain with an explanation of the assay protocol).

In addition we are keen to know the history of the strain, whether laboratory derived or from a clinical isolate.

Finally, it is important to clarify whether the parasites have been cloned and whether information on the genetic basis for resistance is known.

Finally, a reasonable budget to facilitate this work and process should be reported.

SUBMISSION CONTACT DETAILS:

Deadline for receipt in MMV office: 12 noon CET March 31st, 2015
Send your 1-2 page letter of interest, electronically to: proposals@mmv.org